Search Results
Results found for "fibrotic diseases"
- Dr. Khaled Abdelrahman, Victoria Rasmussen and Madelyn Moore | Dr. GPCR Ecosystem
in a sex-selective manner and how this can influence drug discovery in the area of neurodegenerative diseases She is currently working to understand the signaling and degradation of GPCRs in disease states to help
- Using-iPSC-derived-models-to-study-GPCR-function | Dr. GPCR Ecosystem
continued reliance on cellular systems that do not adequately reflect the complexity of human tissues and disease
- Dopamine-Mediated Motor Recovery after Ischemic Stroke
development of new therapeutic interventions for the alleviation of L-DOPA-induced dyskinesia in Parkinson’s Disease
- Abstract Submission Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
categories max) Abstract categories Signaling Trafficking Metabolism Structure and Bioinformatics Health and Disease
- Dr. Pierre Eftekhari | Dr. GPCR Ecosystem
and clinical pharmacology as scientist or PI in neonatal lupus, Cardiomyopathy, hypertension, chagas disease
- Dr. Neil Grimsey | Dr. GPCR Ecosystem
My group studies the spatiotemporal dynamics of atypical inflammation and the control of disease progression
- A positive Allosteric Modulator of M1 Acetylcholine Receptors Improves Cognitive Deficits in Male and Female Alzheimer’s Mice
in a sex-selective manner and how this can influence drug discovery in the area of neurodegenerative diseases
- Dr. Roger Sunahara | Dr. GPCR Ecosystem
studies to address the functional role of these dramatic conformational changes and the relationship to disease continues to engineer the enzyme to optimize its potential as a treatment for cocaine abuse, a debilitating disease
- Dr. Shivani Sachdev | Dr. GPCR Ecosystem
Sachdev is an early career researcher in the National Institute of Diabetes and Digestive and Kidney Diseases
- Dr. Benjamin Myers | Dr. GPCR Ecosystem
tiny antenna-shaped structure at the cell surface with critical links to development, physiology, and disease
- Dr. Kenneth A. Jacobson | Dr. GPCR Ecosystem
In 1983, he joined the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the
- Dylan Eiger | Dr. GPCR Ecosystem
his research on biased agonism at GPCRs with a particular focus on the treatment of cardiovascular disease
- Dr. GPCR Team | Dr. GPCR Ecosystem
Sachdev is an early career researcher in the National Institute of Diabetes and Digestive and Kidney Diseases he aims to apply this knowledge to develop novel chemical treatments for neuronal and cardiovascular diseases
- Dr. Nicola J. Smith | Dr. GPCR Ecosystem
a track record in exploring GPCR structure-function relationships in the context of cardiovascular disease
- Dr. Khaled Abdelrahman | Dr. GPCR Ecosystem
in a sex-selective manner and how this can influence drug discovery in the area of neurodegenerative diseases
- Dr. Sai Prasad Pydi | Dr. GPCR Ecosystem
Jurgen Wess’s lab at the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) - NIH,
- Developing new tools to uncover GPCR signaling patterns with Remi Janicot | Dr. GPCR Ecosystem
Overall, the lab works on diverse models and diseases, and has developed a wide array of tools to dissect
- Atypical Structure and Function of Typical Chemokine Receptors
Our laboratory is working to help patients by developing genetically-modified mice that have disease-causing
- Interaction with the cell adhesion molecule NEGR1 affects mGluR5 cell signalling
were shown to be very effective to rescue the cell death observed in a mouse model of Huntington’s disease
- Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer
second area of interest has been the elucidation of the molecular basis for a rare autosomal human disease
- Dr. Arthur Christopoulos | Dr. GPCR Ecosystem
, molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease work has been applied to studies encompassing neurological and psychiatric disorders, cardiovascular disease Lastly, they discussed the progress of new drugs targeting specific receptors for various diseases, with
- Dr. Arthur Christopoulos | Dr. GPCR Ecosystem
, molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease work has been applied to studies encompassing neurological and psychiatric disorders, cardiovascular disease Lastly, they discussed the progress of new drugs targeting specific receptors for various diseases, with
- Dr. Rosie Dawaliby | Dr. GPCR Ecosystem
Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases
- Dr. Yamina Berchiche | Dr. GPCR Ecosystem
and pharmacology can provide new opportunities to improve our understanding of human physiology and disease
- Dr. Stephane Angers | Dr. GPCR Ecosystem
of growth factors and their signaling mechanisms in development, adult tissue homeostasis, and human diseases
- Dr. Caron Tribute Part 2 | Dr. GPCR Ecosystem
neurotransmitters and how they might underlie brain and behavior disorders such as schizophrenia, Parkinson's disease
- Dr. Caron Tribute Part 1 | Dr. GPCR Ecosystem
neurotransmitters and how they might underlie brain and behavior disorders such as schizophrenia, Parkinson's disease
- Dr. Tobi Langenhan | Dr. GPCR Ecosystem
physiological and pharmacological principles that underlie the workings of adhesion GPCRs in health and disease
- Dr. Caron Tribute Part 3 | Dr. GPCR Ecosystem
neurotransmitters and how they might underlie brain and behavior disorders such as schizophrenia, Parkinson's disease
- Irfan Dhanidina, Dr. Kathleen Caron and Dr. Lauren Slosky | Dr. GPCR Ecosystem
laboratory has gained valuable insights into the genetic basis and pathophysiology of lymphatic vascular disease , preeclampsia and sex-dependent cardiovascular disease.





























